Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CDX-0158 (formerly known as KTN-0158)
CDX-0158 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CDX-0158 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CDX-0158 (formerly known as KTN-0158) | BIOLOGICAL | Single agent CDX-0158 until unacceptable toxicity or progressive disease |
Inclusion Criteria: 1. Written informed consent and any locally required authorization (eg, HIPAA) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations. 2. Metastatic or unresectable cancer that expresses KIT as document...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
CDX-0158 is an investigational monoclonal antibody developed by Celldex Therapeutics for advanced cancer. It is a biomarker-selected therapy, meaning patients are screened for a relevant marker before treatment. CDX-0158 has been studied in a single Phase 1 clinical trial and is not an approved medicine.
CDX-0158 was studied for the treatment of advanced cancer, specifically advanced solid tumors in adults. The research enrolled patients 18 years and older with advanced disease. It remains an investigational agent and has not been approved for any indication.
CDX-0158 targets KIT, a protein receptor also known as CD117. By binding KIT, the monoclonal antibody is designed to interfere with signaling that supports tumor cell growth. KIT is a recognized target in several cancer types, and CDX-0158 was developed as a biomarker-selected therapy directed at this protein.
CDX-0158 is being developed by Celldex Therapeutics, Inc., which trades on the Nasdaq under the ticker CLDX. The company sponsored the clinical program evaluating the antibody in patients with advanced solid tumors.
CDX-0158 is in Phase 1 development. Its only recorded clinical trial, NCT02642016, has been completed, and no trials are currently active. The study was a Phase 1 evaluation of safety and pharmacokinetics in adult patients with advanced solid tumors.
CDX-0158 has been evaluated in one clinical trial, NCT02642016, titled a study to evaluate the safety and pharmacokinetics of CDX-0158 in adult patients with advanced solid tumors. The Phase 1 trial was completed, enrolled 28 patients in the United States, and was an uncontrolled, non-randomized study.
Yes. CDX-0158 was formerly known as KTN-0158, so the two names refer to the same monoclonal antibody. References to KTN-0158 describe the same investigational KIT-targeted agent now identified as CDX-0158 under Celldex Therapeutics.